Rakuten Investment Management Inc. Takes $5.27 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Rakuten Investment Management Inc. acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,961 shares of the biopharmaceutical company’s stock, valued at approximately $5,272,000.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $895,816,000. Legal & General Group Plc purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth about $278,321,000. Qube Research & Technologies Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $369,943,000. AQR Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after buying an additional 555,759 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $148,128,000. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright reduced their target price on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a report on Friday, July 31st. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Sanford C. Bernstein reiterated an “outperform” rating and set a $376.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Oppenheimer dropped their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:ALNY opened at $237.10 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The business has a 50 day simple moving average of $262.62 and a two-hundred day simple moving average of $293.73. The firm has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.